Epirubicina ad alte dosi: vantaggi di un trattamento dilazionato

Of the various therapeutic agents used in the intravesical treatment of superficial bladder cancer, epirubicin has proved active and is today widely used. Its effectiveness is in proportion to the dose, as are the onset and severity of side effects. The aim of this work was to check if a split administration of epirubicin at high doses could reduce the frequency and intensity of the side effects tied to traditional, high-dose intravesical treatment. An attempt was made at the same time to assess its activity within our therapeutic protocol. In conclusion, the split, high-dose treatment with intravesical epirubicin of superficial bladder cancer with intermediate risk was well tolerated in terms of side effects and was effective.